Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ondansetron controlled-release - RedHill Biopharma

Next Previous
X
Search
Drug Profile

Ondansetron controlled-release - RedHill Biopharma

Alternative Names: BEKINDA; Bimodal release ondansetron; CDT-ondansetron; RHB-102

Latest Information Update: 07 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SCOLR Pharma
  • Developer RedHill Biopharma
  • Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastritis; Gastroenteritis
  • Phase II Irritable bowel syndrome
  • Preregistration Submission Withdrawal Radiotherapy-induced nausea and vomiting
  • No development reported Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 05 Sep 2023 RedHill Biopharma has patent protection for Ondansetron controlled-release for treating nausea, vomiting or diarrhea symptoms in Europe
  • 09 May 2023 RedHill Biopharma plans a confirmatory phase III trial for gastroenteritis and gastritis
  • 09 May 2023 RedHill Biopharma plans a phase III trial for irritable bowel syndrome with diarrhoea (IBS-D)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top